Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Vicineum in BCG-Unresponsive High-Grade NMIBC
NCT03258593Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Aug 2022
- Modality
- scFv Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and oportuzumab monatox in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Number of Grades 1-5 Adverse Events at 315 days. Started Jun 2018; status: completed.
02
Drugs
durvalumaboportuzumab monatox
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03258593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258593.